Wordt geladen...
Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway
BACKGROUND: Temozolomide (TMZ) is a first‐line chemotherapy drug for the treatment of malignant glioma and resistance to it poses a major challenge. Receptor‐interacting protein 2 (RIP2) is associated with the malignant character of cancer cells. However, it remains unclear whether RIP2 is involved...
Bewaard in:
| Gepubliceerd in: | CNS Neurosci Ther |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8025621/ https://ncbi.nlm.nih.gov/pubmed/33460245 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13591 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|